Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

141. Breast Cancer Treatment: A Review. (Abstract)

Breast Cancer Treatment: A Review. Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer.Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors (...) and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). More than 90% of breast cancers are not metastatic at the time of diagnosis. For people presenting without metastatic disease, therapeutic goals are tumor eradication and preventing recurrence. Triple-negative breast cancer is more likely to recur than the other 2 subtypes, with 85% 5

2019 JAMA

142. Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer Full Text available with Trip Pro

Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01160 Journal of Clinical Oncology - published online before print November 19, 2018 PMID (...) : Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update , MD, PhD 1 x Harold J. Burstein ; , MHSc 2 x Christina Lacchetti ; , RN 3 x Holly Anderson ; , MD 4 x Thomas A. Buchholz ; , MD 5 x Nancy E. Davidson ; , MD 6 x Karen A. Gelmon ; , MD 4 x Sharon H. Giordano ; , MD 7 x Clifford A. Hudis ; , MD 8 x Alexander J. Solky ; , MD 9 x Vered Stearns ; , MD 1 x Eric P. Winer ; and , MD 10 x Jennifer J. Griggs 1Dana-Farber Cancer

2019 American Society of Clinical Oncology Guidelines

143. Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer

Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer 1 Published 14 January 2019 1 a SMC2120 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE (...) : following a third resubmission assessed under the orphan equivalent process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: In combination with trastuzumab and docetaxel, in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Addition of pertuzumab to current first-line treatment, trastuzumab plus docetaxel, significantly

2019 Scottish Medicines Consortium

144. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer T T umour profiling tests to guide adjuvant umour profiling tests to guide adjuvant chemother chemotherap apy decisions in early breast y decisions in early breast cancer cancer Diagnostics guidance Published: 19 December 2018 nice.org.uk/guidance/dg34 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 56Contents Contents 1 Recommendations 4 2 Clinical need and practice 6 The problem addressed 6 The condition 7 The diagnostics and care pathways 7 3 The diagnostic tests 9 The interventions 9 The comparator 13 4 Evidence 14

2019 National Institute for Health and Clinical Excellence - Diagnostics Guidance

145. Trastuzumab (Ogivri) - breast cancer or stomach cancer

Trastuzumab (Ogivri) - breast cancer or stomach cancer 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions 1. NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (...) for solution for infusion (powder for concentrate). White to pale yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Breast cancer Metastatic breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless

2019 European Medicines Agency - EPARs

146. A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer Full Text available with Trip Pro

A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer To systematically evaluate the safety, feasibility, and effect of exercise among women with stage II+ breast cancer.CINAHL, Cochrane, Ebscohost, MEDLINE, Pubmed, ProQuest Health and Medical Complete, ProQuest Nursing and Allied Health Source, Science Direct and SPORTDiscus were searched for articles published before March 1, 2017.Randomized, controlled, exercise trials (...) involving at least 50% of women diagnosed with stage II+ breast cancer were included.Risk of bias was assessed and adverse event severity was classified using the Common Terminology Criteria. Feasibility was evaluated by computing median (range) recruitment, withdrawal, and adherence rates. Meta-analyses were performed to evaluate exercise safety and effects on health outcomes only. The influence of intervention characteristics (mode, supervision, duration and timing) on exercise outcomes were also

2019 EvidenceUpdates

147. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial (Abstract)

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared with a carboplatin-taxane regimen, when given in combination with the HER2 (...) -targeted agents trastuzumab and pertuzumab.The TRAIN-2 study is an open-label, randomised, controlled, phase 3 trial being done in 37 hospitals in the Netherlands. We recruited patients aged 18 years or older with previously untreated, histologically confirmed stage II-III HER2-positive breast cancer. Patients were randomly allocated using central randomisation software (1:1 ratio) with minimisation without a random component, stratified by tumour stage, nodal stage, oestrogen receptor status, and age

2019 EvidenceUpdates

148. Thermography versus standard diagnostic/screening methods used in India to detect breast cancer - a systematic review protocol

Thermography versus standard diagnostic/screening methods used in India to detect breast cancer - a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

149. Interventions in patients with positive screening of breast cancer for the decrease of wait times for diagnosis and treatment

Interventions in patients with positive screening of breast cancer for the decrease of wait times for diagnosis and treatment Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

150. Is nab-paclitaxel definitely a better choice than conventional paclitaxel for advanced breast cancer? a systemic review and meta-analysis

Is nab-paclitaxel definitely a better choice than conventional paclitaxel for advanced breast cancer? a systemic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

151. Effectiveness and safety of intraoperative radiotherapy with electrons in patients with breast cancer. Systematic review of the literature

Effectiveness and safety of intraoperative radiotherapy with electrons in patients with breast cancer. Systematic review of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

152. Draft protocol for a systematic review of research on the cost-effectiveness of intraoperative radiotherapy (IORT) in early-stage breast cancer patients

Draft protocol for a systematic review of research on the cost-effectiveness of intraoperative radiotherapy (IORT) in early-stage breast cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

153. Exercise for fatigue in breast cancer patients: an umbrella review of systematic review

Exercise for fatigue in breast cancer patients: an umbrella review of systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

154. Evidence brief: accuracy of self-report for cervical and breast cancer screening

Evidence brief: accuracy of self-report for cervical and breast cancer screening Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

155. Breast and colorectal cancer awareness in Malaysians and barriers towards screening: a systematic review

Breast and colorectal cancer awareness in Malaysians and barriers towards screening: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

156. Bisphosphonates or denosumab for patients with breast cancer and bone metastases: a systematic review and network meta-analysis of randomized controlled trials

Bisphosphonates or denosumab for patients with breast cancer and bone metastases: a systematic review and network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

157. Being a caregiver to patients with breast cancer in low -and middle- income countries: a systematic review protocol

Being a caregiver to patients with breast cancer in low -and middle- income countries: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

158. Diagnostic value of mammography associated to ultrasonography versus breast MRI abbreviated protocol for breast cancer screening in dense breasts at average risk: systematic review

Diagnostic value of mammography associated to ultrasonography versus breast MRI abbreviated protocol for breast cancer screening in dense breasts at average risk: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

159. The association between widowhood and breast cancer risk: a systematic review and meta-analysis study

The association between widowhood and breast cancer risk: a systematic review and meta-analysis study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

160. Systematic review: decision aids for women considering breast cancer surgery

Systematic review: decision aids for women considering breast cancer surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2019 PROSPERO